|
Pharmacokinetic (PK) characterization of irinotecan liposome injection in patients (pts) with metastatic breast cancer (mBC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - OncoSec (I) |
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals |
Consulting or Advisory Role - HUYA Bioscience International |
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst) |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); TapImmune Inc. (Inst); Tesaro (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Biovica; Lilly; Merck; Novartis; Pfizer; Pfizer; Puma Biotechnology; Syndax; Tempus |
Research Funding - Eisai (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; pfizer; Syndax |